rs33985544
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM2PM5PP3_StrongPP5
The NM_000518.5(HBB):c.191A>G(p.His64Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. H64Y) has been classified as Pathogenic.
Frequency
Consequence
NM_000518.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HBB | NM_000518.5 | c.191A>G | p.His64Arg | missense_variant | 2/3 | ENST00000335295.4 | NP_000509.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HBB | ENST00000335295.4 | c.191A>G | p.His64Arg | missense_variant | 2/3 | 1 | NM_000518.5 | ENSP00000333994.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 36
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:1Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Sep 28, 2022 | The Hb Zurich variant (HBB: c.191A>G; p.His64Arg, also known as His63Arg when numbered from the mature protein, rs33985544, HbVar ID: 358) has been observed in the heterozygous state in asymptomatic individuals or associated with mild reticulocytosis (see HbVar database and references therein). This variant has been associated with episodes of severe drug-induced hemolytic anemia in patients after administration of oxidative drugs particularly sulfonamides (see HbVar, Aguinaga 1998, Miranda 1994). This variant has been reported as mildly unstable with increased oxygen affinity (Aguinaga 1998). This variant is reported in ClinVar (Variation ID: 15400) and is absent from the Genome Aggregation Database, indicating it is not a common polymorphism. The histidine at codon 64 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.983). Based on available information, this variant is considered to be likely pathogenic. References: Link to HbVar database: https://globin.bx.psu.edu/hbvar/menu.html Aguinaga MP et al. Molecular diagnosis and characterization of Hb Zürich [beta63(E7)His-->Arg]] carriers in a Kentucky family. Hemoglobin. 1998 Sep-Nov;22(5-6):509-15. PMID: 9859934. Miranda SR et al. Identification of Hb Zürich [alpha 2 beta 2(63)(E7)His-->Arg] by DNA analysis in a Brazilian family. Hemoglobin. 1994 Sep;18(4-5):337-41. PMID: 7852089. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jan 08, 2020 | - - |
Hemoglobinopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 22, 2024 | Variant summary: HBB c.191A>G (p.His64Arg) results in a non-conservative amino acid change in the encoded protein sequence, altering a conserved residue (HGMD) in which another missense variant (p.His64Tyr) is classified as pathogenic. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251428 control chromosomes (gnomAD). c.191A>G has been reported in the literature in heterozygous individuals affected with hemolytic episodes, which was usually described as following sulfonamide treatment, as well as in healthy relatives (e.g. Huisman_1961, Frick_1962, Rieder_1965, Dickerman_1973, Murata_1982, Miranda_1994, Aguinaga_1998). It was also found in the compound heterozygous state with a pathogenic variant in an individual with a phenotype ressembling beta thalassemia intermedia (Yan_2019). These data indicate that the variant is likely associated with hemoglobinopathy in the heterozygous state which manifests as a drug-induced reaction, and may also be associated with disease in the compound heterozygous state with a beta thalassemia allele. Publications report experimental evidence evaluating an impact on protein function (Zinkham_1980, Aguinaga_1998), finding evidence of protein instability and increased carbon monoxide affinity. The following publications have been ascertained in the context of this evaluation (PMID: 6175783, 13716725, 14314237, 4749206, 13895148, 7852089, 9859934, 7384813, 30900795). ClinVar contains an entry for this variant (Variation ID: 15400). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Other:1
other, no assertion criteria provided | literature only | OMIM | Sep 01, 1998 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at